BTG plc (LSE: BTG), a global specialist healthcare company, today announced the treatment of an Australian patient with DC Bead LUMI(TM), a next-generation development of the market leading DC Bead(R). DC Bead LUMI(TM) is the first commercially available Radiopaque Drug-Eluting Bead which can be loaded with doxorubicin or irinotecan for the local treatment of tumours in patients with hepatocellular carcinoma (HCC) and liver metastases from colorectal cancer (mCRC), respectively.
DC Bead LUMI(TM) offers a personalised approach to treatment and a new level of control to TACE procedures. The lasting radiopacity allows the physician to see rather than assume where the beads are placed in the tumour, providing reassurance to patients that the treatment is getting to where it needs to be.
Dr Anthony Wilkinson, BTG Regional Medical Director
